Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodophyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes;
Rituximab: MabThera, Rituxan: mab: chimeric: CD20: Y [109] lymphomas, leukemias, some autoimmune disorders Rivabazumab pegol [12] mab: humanized: Pseudomonas aeruginosa type III secretion system: Robatumumab: mab: human: IGF-1 receptor (CD221) cancer Rmab: RabiShield: human: rabies virus G glycoprotein: Y: post-exposure prophylaxis of rabies ...
Peripherally selective drugs have their primary mechanism of action outside of the central nervous system (CNS), usually because they are excluded from the CNS by the blood–brain barrier. By being excluded from the CNS, drugs may act on the rest of the body without producing side-effects related to their effects on the brain or spinal cord .
Severe disease is typically treated with a combination of immunosuppressive medications such as rituximab or cyclophosphamide and high-dose corticosteroids to control the symptoms of the disease and azathioprine, methotrexate, or rituximab to keep the disease under control.
The display was all the more remarkable given how recently many in tech were politically naive or apathetic. Column: The rise of Silicon Valley, from indifference to lords of the political universe
Treatments include rituximab, either alone or combined with chemotherapy; obinutuzumab; combination immunotherapy with lenalidomide and rituximab; and radiolabeled monoclonal antibody therapy. Phosphatidylinositol 3-kinase (PI3K) inhibitors such as copanlisib, idelalisib, or duvelisib may be used to treat relapsed indolent lymphoma. [27]
More recently, the immunotherapy drug, rituximab has been added to the CHOP chemotherapy regiment to form the R-CHOP chemoimmunotherapy regimen. [2] Rituximab is a monoclonal antibody that binds to the CD20 protein on, e.g. B-cells, and by doing so targets these cells for attack by the hosts adaptive immune system. [13]